More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$17.54B
EPS
3.48
P/E ratio
70.3
Price to sales
6.75
Dividend yield
--
Beta
1.411132
Previous close
$241.89
Today's open
$245.85
Day's range
$243.67 - $250.41
52 week range
$230.05 - $354.88
show more
CEO
Ashley McEvoy
Employees
3900
Headquarters
Acton, MA
Exchange
Nasdaq Global Select
Shares outstanding
70346898
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Insulet Q4 Earnings Review: Strong Performance Meets Sky-High Expectations
Insulet Q4 Earnings Review: Strong Performance Meets Sky-High Expectations
Seeking Alpha • Feb 19, 2026

PODD Stock Up on Q4 Earnings & Revenue Beat, Margins Rise
Insulet jumps after Q4 EPS and revenue beat, margin expansion and record Omnipod growth power a strong 2025 finish and upbeat 2026 outlook.
Zacks Investment Research • Feb 19, 2026

Insulet beats quarterly estimates on strong demand for wearable insulin pumps
Insulet reported better-than-expected fourth-quarter results on Wednesday, on the back of strong demand for its tubeless insulin pumps that eliminate the need for daily injections.
Reuters • Feb 18, 2026

Insulet Corporation (PODD) Q4 2025 Earnings Call Transcript
Insulet Corporation (PODD) Q4 2025 Earnings Call Transcript
Seeking Alpha • Feb 18, 2026

Insulet Reports Fourth Quarter and Full Year 2025 Results
ACTON, Mass.--(BUSINESS WIRE)--Insulet Reports Fourth Quarter and Full Year 2025 Results.
Business Wire • Feb 18, 2026

Diabetes-Focused Insulet Forecasts Strong 2026 Growth, Stock Soars
Insulet Corporation (NASDAQ: PODD) stock is trading higher on Wednesday after the company reported better-than-expected fourth-quarter earnings and 2026 guidance.
Benzinga • Feb 18, 2026

Insulet (PODD) Tops Q4 Earnings and Revenue Estimates
Insulet (PODD) came out with quarterly earnings of $1.55 per share, beating the Zacks Consensus Estimate of $1.48 per share. This compares to earnings of $1.15 per share a year ago.
Zacks Investment Research • Feb 18, 2026

Insulet (PODD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Insulet (PODD) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks Investment Research • Feb 18, 2026

Exploring Analyst Estimates for Insulet (PODD) Q4 Earnings, Beyond Revenue and EPS
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Insulet (PODD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Zacks Investment Research • Feb 12, 2026

Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Feb 11, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Insulet Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.